Professional sanitary work with biological samples.
La Sanitary crisis provoked by Covid-19 pandemic ha hecho that the pharmaceutical industry has centralized its efforts to find an effective treatment to lighten up against this illness. If the carrier for the vacancies against this coronavirus is stored in less than one year, the search for a pharmacy able to slow down the advance of Covid is designed to be similar in nature.
In this sense, the drug agencies have been in charge of the industry to assess and collaborate in this research process. From the European Medicines Agency (EMA, by its sailors in English) has maintained a constant dialogue with pharmacists for assessors during the clinical and preclinical phase. All to “allow the candidates to take medication lleguen a los patient de la Unión Europea (UE) is possible”, As seen from the organization.
Además, the European agency also signaled that it wanted “assist the industry in the preparation of authorization applications of commercialization ”, a fundamental step for these potential drugs against the Covid-19 lleguen a todos los paises miembros de la Unión Europea.
In the published list of treatment against the Covid which are located in clinical phase, are located the following pharmacological:
Pharmacists Immunomodulators
-
Treatment: APN01, developed by Apeiron Biologics.
-
Treatment: Apremilast, developed by Amgen Europe BV.
-
Treatment: D24Fc, developed by Oncoimmune Inc.
-
Treatment: Acalabrutinib, developed by Acerta Pharma BV y AstraZeneca.
-
Treatment: Baricitinib, developed by Eli Lilly.
-
Treatment: Colchicine, developed by Pharmaceutical Science (PMS) y el Montreal Health Institute (MHI).
-
Treatment: Eculizumab, developed by Alexion.
-
Treatment: Emapalumab and anakinra, developed by Swedish Orphan Biovitrum AB (SOBI).
-
Treatment: Gimsilumab, developed by Roivant.
-
Treatment: Sarilumab, developed by Sanofi Aventis.
-
Treatment: Siltuximab, developed by EUSApharma.
-
Treatment: SNG001, developed by Synairgen Research Limited.
-
Treatment: Tocilizumab, developed by Roche.
Antiviral drugs
-
Treatment: Human immunoglobulin enriched with IgM (Trimodulin) (BT588), developed by Biotest AG.
-
Treatment: AT-527, unlocked by Roche.
-
Treatment: ABBV-47D11, developed by AbbVie.
-
Treatment: Immunoglobulin hyperinmune anti-SARS-CoV-2 policing, developed in the Alliance Hyperinmune Project between Biotest AG, Laboratoio de Bioproductos, LFB, Octapharma, CSL Behring and Takeda.
-
Treatment: Cobruro de cobre, developed by ACOM.
-
Treatment: CoviFab, developed by Inmunova SA and mbxience.
-
Treatment: Danoprevir, developed by Ascletis Pharmaceuticals Co. Ltd.
-
Treatment: Favipiravir, developed by Glenmark Pharmaceuticals Ltd.
-
Treatment: RBT-9, developed by Renibus Therapeutics Inc.
-
Treatment: Remdesivir, developed by Galaad.
-
Treatment: UNI911, developed by Union Therapeutics.
Monoclonal anticancer drugs
-
Treatment: Itolizumab, developed by Biocon Biologics Limited.
-
Treatment: SCTA01, developed by Sinocelltech Bpk.
-
Treatment: VIR-7831, VIR-7832, developed by For Biotechnology y GSK.
Pharmacies with other types of therapies not specified
-
Treatment: Aviptadil, developed by Relief Therapeutics Holding SA.
-
Treatment: BI 764198, developed by Boehringer Ingelheim International GmbH.
-
Treatment: Chloroquina, developed by the University of Oxford.
-
Treatment: Chloroquine and hydroxychloroquine cyclope DPI, developed by PureIMS.
-
Treatment: Emiplacel, developed by Biopharma Excellence GmbH.
-
Treatment: Ravulizumab, developed by Alexion.
Although it contains statements, dates or appointments of institutions or health care professionals, the information contained in Redacción Médica is edited and elaborated by periodicals. We recommend to the reader that any relationship with the health be consulted with a health care professional.